← Browse by Condition
Medical Condition
acute myeloid leukemia in relapse
Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1
NCT05190471 Phase 1
Recruiting
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Enrollment
48 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
NCT05546580 Phase 1
Recruiting
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Enrollment
50 pts
Location
United States
Sponsor
Oryzon Genomics S.A.
NCT06552416 Phase 1
Recruiting
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Enrollment
40 pts
Location
United States
Sponsor
Marker Therapeutics, Inc.